Founded in 2020, Overland Pharmaceuticals is establishing a leading cross-border platform company focused on advanced modalities through strategic partnering and in-house R&D. Overland is seeded by Hillhouse Capital with access to global innovation and China biopharma ecosystem.

Overland is building an initial oncology portfolio of first-in-class ADC and allogeneic cell therapy programs for greater China and Asia through partnering with established biotechs.

Through formative R&D partnerships and in-house technology platforms, Overland will move forward the development and commercialization of the most promising advances in medicine.

Biotechnology

Health Care

Life Sciences

Therapeutics

Overland Pharmaceuticals

Ed Zhang

Wendy Yang

Sophie Chen

Eric H.

Yi-Shin Lai

Chia-Wei Chang

Weimin Li

Weijie Lan

The Research and Development team at Overland Pharmaceuticals is responsible for pioneering and advancing innovative oncology therapies, including first-in-class ADC and allogeneic cell therapy programs, tailored for the greater China and Asia markets. Comprised of scientists, senior scientists, lab managers, and directors specializing in cell therapy and engineering, this team leverages both strategic global partnerships and internal technology platforms to develop and commercialize leading-edge medical treatments.

Research and Development

Leadership Team

Research and Development

About

Team members

Other teams at Overland Pharmaceuticals

Leadership Team